News & Updates
Filter by Specialty:
Linerixibat quells cholestatic itch in PBC, enabling better sleep
The ileal bile acid transporter inhibitor linerixibat provides rapid and substantial relief from cholestatic pruritus, in turn reducing associated sleep disturbances, in patients with primary biliary cholangitis (PBC), as shown in the global, phase III GLISTEN trial.
Linerixibat quells cholestatic itch in PBC, enabling better sleep
23 May 2025
SOF/VEL combo improves well-being of children with CHC
In children with chronic hepatitis C (CHC), effective treatment with sofosbuvir/velpatasvir (SOF/VEL) results in improvements in certain areas of their well-being at 1 year. This suggests some patient-reported outcomes (PRO) benefits of direct-acting antiviral (DAA) therapy. However, the parents’ proxy reports show a decrease in the patients’ school functioning.
SOF/VEL combo improves well-being of children with CHC
27 Apr 2025
Maternal TDF, infant HBV vax, HBIg-free strategy prevent infant hep B
In the absence of infant hepatitis B immune globulin (HBIg), maternal tenofovir disoproxil fumarate (TDF) prophylaxis combined with infant hepatitis B virus (HBV) immunization provide sufficient protection against HBV infection in infants, findings from the iTAP-2 study suggest. However, the risk of infection was not demonstrably below 2 percent.